MCID: INF023
MIFTS: 53

Inflammatory Breast Carcinoma

Categories: Rare diseases, Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 15 73
Inflammatory Breast Cancer 76 53 55
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 44
Breast Cancer, Inflammatory 53
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 44 D058922
NCIt 50 C4001
SNOMED-CT 68 254840009
UMLS 73 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 53 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.” The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions.

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to adenocarcinoma and fallopian tube carcinoma, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Capecitabine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and prostate, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased viability with paclitaxel

Wikipedia : 76 Inflammatory breast cancer is one of the most aggressive types of breast cancer that can occur in women... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 28.8 CDH1 EGFR ERBB2
2 fallopian tube carcinoma 28.5 ERBB2 ESR1 PGR
3 breast cystic hypersecretory carcinoma 10.3 CDH1 ERBB2
4 comedo carcinoma 10.3 ERBB2 ESR1
5 breast intraductal proliferative lesion 10.2 EGFR ERBB2
6 vulvar syringoma 10.1 ESR1 PGR
7 lung leiomyoma 10.1 ESR1 PGR
8 vestibular gland benign neoplasm 10.1 ESR1 PGR
9 bartholin's gland adenoma 10.1 ESR1 PGR
10 vulvar benign neoplasm 10.1 ESR1 PGR
11 trigonitis 10.1 ESR1 PGR
12 vulvar leiomyoma 10.1 ESR1 PGR
13 predominantly cortical thymoma 10.1 ESR1 PGR
14 progesterone resistance 10.1 ESR1 PGR
15 cribriform carcinoma 10.1 ESR1 PGR
16 endometrial squamous cell carcinoma 10.0 ESR1 PGR
17 endometrial mucinous adenocarcinoma 10.0 ESR1 PGR
18 adenoid basal cell carcinoma 10.0 ESR1 PGR
19 gender identity disorder 10.0 ESR1 PGR
20 bartholin's gland benign neoplasm 10.0 ESR1 PGR
21 deep angioma 10.0 ESR1 PGR
22 acneiform dermatitis 10.0 EGFR ERBB2
23 synchronous bilateral breast carcinoma 10.0 ESR1 PGR
24 cervical carcinosarcoma 10.0 ESR1 PGR
25 adenosquamous cell lung carcinoma 10.0 EGFR ERBB2
26 estrogen excess 10.0 ESR1 PGR
27 intramuscular hemangioma 10.0 ESR1 PGR
28 glycogen-rich clear cell breast carcinoma 10.0 ESR1 PGR
29 mammographic density 10.0 ESR1 PGR
30 retinitis pigmentosa 47 10.0 ESR1 PGR
31 adenomyosis 10.0 ESR1 PGR
32 retinitis pigmentosa 20 10.0 ESR1 PGR
33 adenosarcoma 10.0 ESR1 PGR
34 cervical clear cell adenocarcinoma 10.0 ESR1 PGR
35 endometriosis of ovary 10.0 ESR1 PGR
36 uterine benign neoplasm 10.0 ESR1 PGR
37 lobular neoplasia 10.0 CDH1 ERBB2 ESR1
38 gallbladder adenocarcinoma 10.0 EGFR ERBB2
39 lymphoma 9.9
40 mastitis 9.9
41 reproductive organ benign neoplasm 9.9 ESR1 PGR
42 smooth muscle tumor 9.9 ESR1 PGR
43 pancreatic mucinous cystadenoma 9.9 ESR1 PGR
44 pharynx cancer 9.9 CDH1 EGFR
45 endometritis 9.9 ESR1 PGR
46 prostatic hypertrophy 9.9 ESR1 PGR
47 small intestinal adenocarcinoma 9.9 EGFR ERBB2
48 breast cancer 9.9
49 erysipeloid 9.9
50 ovarian cancer 1 9.9 CDH1 ERBB2

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema, pain, peau d'orange

GenomeRNAi Phenotypes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.43 CDH1 ERBB2 ESR1 FUT3 PGR PROX1
2 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 ESR1 CDH1 PGR EGFR PROX1 ERBB2
2 endocrine/exocrine gland MP:0005379 9.87 CDH1 PGR EGFR PROX1 WISP3 ERBB2
3 digestive/alimentary MP:0005381 9.8 ESR1 CDH1 EGFR PROX1 ERBB2
4 embryo MP:0005380 9.77 ESR1 CDH1 PGR EGFR ERBB2
5 integument MP:0010771 9.73 CDH1 PGR EGFR WISP3 ERBB2 ESR1
6 muscle MP:0005369 9.55 ESR1 PGR EGFR PROX1 ERBB2
7 neoplasm MP:0002006 9.43 CDH1 PGR EGFR WISP3 ERBB2 ESR1
8 normal MP:0002873 9.17 CDH1 PGR EGFR PROX1 WISP3 ERBB2

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 154361-50-9 60953
2
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
7
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
9
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
10
Goserelin Approved Phase 2, Phase 3,Phase 3 65807-02-5 47725 5311128
11
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
12
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 180288-69-1 9903
13
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
16
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
17
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
18
Prochlorperazine Approved, Vet_approved Phase 3 1984-02-6, 58-38-8 4917
19
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
20
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
21
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
23
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
24
Palonosetron Approved, Investigational Phase 3 135729-61-2, 119904-90-4, 135729-56-5 148211
25
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
26
Fosaprepitant Approved Phase 3 172673-20-0 219090
27
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
28
Adenosine Approved, Investigational Phase 3 58-61-7 60961
29
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
30
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
33
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
34
Substance P Investigational Phase 3 33507-63-0 44359816
35 Progestins Phase 3,Phase 2
36 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
38 Folic Acid Antagonists Phase 3
39 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
40 Gastrointestinal Agents Phase 3,Early Phase 1
41 Steroid Synthesis Inhibitors Phase 2, Phase 3
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormone Antagonists Phase 3,Phase 2,Phase 1
44 Dermatologic Agents Phase 3
45 Nucleic Acid Synthesis Inhibitors Phase 3
46 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 Combination Chemotherapy in Treating Women With Breast Cancer Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
3 Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
4 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
5 Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
6 Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
7 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
8 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
9 S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
10 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
11 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
12 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
13 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
14 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
15 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting NCT02003209 Phase 3 Aromatase Inhibition Therapy;Carboplatin;Docetaxel;Goserelin Acetate
16 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT02131064 Phase 3 Carboplatin;Docetaxel;Pertuzumab;Trastuzumab;Trastuzumab Emtansine
17 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
18 Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Terminated NCT00028704 Phase 3
19 Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
20 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
21 Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
22 Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
23 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
24 Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
25 Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
26 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
27 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
28 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
29 Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
30 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
31 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
32 Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin
33 Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
34 Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
35 A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer Completed NCT00001193 Phase 2
36 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
37 Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
38 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
39 Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
40 Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer Completed NCT00450892 Phase 1, Phase 2 docetaxel+lapatinib;docetaxel + trastuzumab;docetaxel + trastuzumab + lapatinib
41 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
42 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
43 Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
44 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
45 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
46 Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer Completed NCT00943410 Phase 2 Herceptin
47 Xeloda (Capecitabine) and External Beam Radiation Completed NCT00916578 Phase 2 Capecitabine
48 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
49 Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer Completed NCT00464646 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Trastuzumab;Bevacizumab
50 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer Completed NCT00559845 Phase 2 5-fluorouracil;Epidoxorubicin;Cyclophosphamide;Paclitaxel

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

41
Breast, Skin, Prostate, Bone, Liver, Lymph Node, B Cells

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 101)
# Title Authors Year
1
Diffuse dermal angiomatosis mimicking inflammatory breast carcinoma. ( 28744985 )
2017
2
Bilateral breast filariasis mimicking inflammatory breast carcinoma. ( 29184008 )
2017
3
Gadolinium-Naive Nephrogenic Systemic Fibrosis of Breast Mimicking Inflammatory Breast Carcinoma. ( 28323787 )
2017
4
Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer. ( 27766674 )
2016
5
Idiopathic granulomatous mastitis mimicking inflammatory breast carcinoma: What are the odds? ( 27790396 )
2016
6
Primary Neuroendocrine Carcinoma of the Breast with Clinical Features of Inflammatory Breast Carcinoma: A Case Report and Literature Review. ( 26770249 )
2015
7
Axillary high-grade B-cell non-Hodgkin lymphoma presenting under the guise of inflammatory breast carcinoma. ( 26670406 )
2015
8
Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides. ( 26345728 )
2015
9
Breast filariasis or inflammatory breast carcinoma? Reaching a diagnosis. ( 26567240 )
2015
10
Axillary lymph node tuberculosis masquerading as inflammatory breast carcinoma in an immune-compromised patient. ( 25681261 )
2015
11
Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies. ( 25417171 )
2015
12
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. ( 24516025 )
2014
13
Collision tumor with inflammatory breast carcinoma and malignant phyllodes tumor: a case report and literature review. ( 24400686 )
2014
14
Comparison between invasive breast cancer with extensive peritumoral vascular invasion and inflammatory breast carcinoma: a clinicopathologic study of 161 cases. ( 25125618 )
2014
15
Inflammatory breast carcinoma. ( 23543972 )
2013
16
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. ( 24156086 )
2013
17
Inflammatory breast carcinoma. ( 23945485 )
2013
18
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib. ( 24201163 )
2013
19
Unusual dermal pleomorphic calcifications in a case of inflammatory breast carcinoma. ( 24082417 )
2013
20
Inflammatory breast carcinoma and locally advanced breast carcinoma: characterisation with MR imaging. ( 20927653 )
2011
21
Gastric cancer in a pregnant woman presenting with low back pain and bilateral erythematous breast hypertrophy mimicking primary inflammatory breast carcinoma. ( 21378356 )
2011
22
A woman with multiple silicone rupture complicated by inflammatory breast carcinoma. ( 21443069 )
2011
23
p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. ( 21252573 )
2011
24
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? ( 21850396 )
2011
25
Image of the month. Inflammatory breast carcinoma. ( 20157092 )
2010
26
Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. ( 20503411 )
2010
27
A case of inflammatory breast carcinoma: carcinoma erysipeloides. ( 20228568 )
2010
28
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. ( 20133250 )
2010
29
Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth. ( 19707200 )
2009
30
Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma. ( 19082616 )
2009
31
Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. ( 19364961 )
2009
32
Fallopian tube cancer presenting as inflammatory breast carcinoma: report of a case and review of the literature. ( 19899419 )
2009
33
Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma. ( 19798691 )
2009
34
Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. ( 18523781 )
2008
35
Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. ( 18206620 )
2008
36
Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. ( 18308143 )
2008
37
Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. ( 17227116 )
2007
38
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. ( 17242702 )
2007
39
Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma. ( 17343591 )
2007
40
Docetaxel administered during pregnancy for inflammatory breast carcinoma. ( 16595038 )
2006
41
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. ( 16444747 )
2006
42
[Biological significance of E-cadherin in an inflammatory breast carcinoma cell line]. ( 16737610 )
2006
43
Unique features of inflammatory breast carcinoma. ( 16094760 )
2005
44
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. ( 15998949 )
2005
45
Imaging in inflammatory breast carcinoma. ( 16735786 )
2005
46
Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. ( 16278382 )
2005
47
Inflammatory breast carcinoma: the sphinx of breast cancer research. ( 14722054 )
2004
48
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. ( 15143076 )
2004
49
Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. ( 14983486 )
2004
50
Long-term results of combined-modality therapy for inflammatory breast carcinoma. ( 15585073 )
2004

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1 12.48 CDH1 EGFR ERBB2 ESR1
2
Show member pathways
12.37 CDH1 EGFR ERBB2 ESR1
3
Show member pathways
12.23 CDH1 EGFR ERBB2
4
Show member pathways
12.22 CDH1 EGFR ERBB2 ESR1 PGR
5
Show member pathways
12.01 EGFR ERBB2 ESR1
6 11.97 EGFR ERBB2 ESR1
7 11.8 CDH1 EGFR ESR1
8
Show member pathways
11.51 EGFR ERBB2 ESR1
9 11.36 CDH1 EGFR ERBB2
10 11.29 CDH1 EGFR ERBB2
11 11.24 EGFR ESR1
12 11.2 EGFR ERBB2
13 11.14 CDH1 EGFR
14 11 EGFR ERBB2
15
Show member pathways
10.96 EGFR ERBB2 ESR1 PGR
16 10.76 CDH1 EGFR
17 10.62 CDH1 EGFR ERBB2

GO Terms for Inflammatory Breast Carcinoma

Cellular components related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 8.62 EGFR ERBB2

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.56 CDH1 EGFR ESR1 PROX1
2 positive regulation of fibroblast proliferation GO:0048146 9.48 EGFR ESR1
3 cellular response to epidermal growth factor stimulus GO:0071364 9.46 EGFR ERBB2
4 ERBB2 signaling pathway GO:0038128 9.43 EGFR ERBB2
5 cellular response to estradiol stimulus GO:0071392 9.4 EGFR ESR1
6 regulation of cell motility GO:2000145 9.37 EGFR ERBB2
7 positive regulation of protein kinase B signaling GO:0051897 9.33 EGFR ERBB2 ESR1
8 regulation of ERK1 and ERK2 cascade GO:0070372 9.32 EGFR ERBB2
9 negative regulation of ERBB signaling pathway GO:1901185 8.96 EGFR ERBB2
10 phosphatidylinositol phosphorylation GO:0046854 8.8 EGFR ERBB2 ESR1

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.65 CDH1 EGFR ERBB2 ESR1 PGR
2 nuclear receptor activity GO:0004879 9.4 ESR1 PGR
3 core promoter sequence-specific DNA binding GO:0001046 9.37 ESR1 PROX1
4 steroid binding GO:0005496 9.32 ESR1 PGR
5 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
6 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGFR ERBB2 ESR1

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....